RecruitingPhase 2NCT05049057

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Enrollment

404 participants

Start Date

Jul 19, 2022

Study Type

INTERVENTIONAL

Conditions

Mild Traumatic Brain Injury Posttraumatic Headache

Summary

This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Erenumab 140 Mg/mL Subcutaneous Solution and a drug called Placebo for people with mild traumatic brain injury and posttraumatic headache. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.